Home/Pipeline/Flutiform

Flutiform

Asthma

MarketedActive

Key Facts

Indication

Asthma

Phase

Marketed

Status

Active

Company

KYORIN Pharmaceutical

About KYORIN Pharmaceutical

KYORIN Pharmaceutical is a publicly listed Japanese pharmaceutical leader with a mission to contribute to people's health by addressing unmet medical needs. Founded in 1923 and publicly listed in 1999, the company has achieved significant scale with a market valuation of ~$94.8B, built on a foundation of established products in respiratory and urology. Its current strategy, outlined in the 'Vision 110' long-term plan, focuses on transforming its business structure to become a core innovator in new pharmaceuticals while expanding its healthcare portfolio.

View full company profile

Therapeutic Areas

Respiratory Urology Otolaryngology Infectious Disease Pain

Other Asthma Drugs

Drug	Company	Phase	Status
Chitinase Inhibitor	Lead Discovery Siena	Discovery	Active
RIG-101	RIGImmune	Pre-clinical	Active
SKB378	Klus Pharma	Phase 1	Active
Asthma Clinical Trials	American Health Research	Not Disclosed	Active
Advanced Asthma Products	Polpharma	Not Disclosed	Active
Solrikitug	Uniquity Bio	Phase 2	Active
CAL-4	Calyxha Biotechnologies	Preclinical	Active
Novel Immunology Candidate	Teva Pharmaceutical Industries	Phase 3	Active
Zumilokibart (APG777)	Apogee Therapeutics	Phase 1	Completed (Phase 1b)
APG808	Apogee Therapeutics	Phase 1b	Interim results reported